Related Experiment Video
Updated: Apr 10, 2026
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
11.6K
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P Bondeson1, Alina Mares2, Ian E D Smith2
1Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut, USA.
Nature Chemical Biology
|June 16, 2015
Summary
Researchers improved proteolysis targeting chimeras (PROTACs) for potent, targeted protein degradation. This new chemical knockdown strategy offers high efficacy at low concentrations with broad tissue distribution, overcoming limitations of traditional drug therapies.
Area of Science:
- Chemical Biology
- Drug Discovery
- Molecular Degradation
Background:
- Current therapies often require high drug concentrations, leading to side effects due to maximal drug-receptor occupancy.
- Existing methods for protein knockdown, like RNAi and CRISPR, have limitations in application and delivery.
- Proteolysis targeting chimeras (PROTACs) offer a novel approach for targeted protein degradation.
Purpose of the Study:
- To present significant advancements in the PROTACs method for efficient chemical knockdown of specific proteins.
- To demonstrate a catalytic mechanism for PROTACs enabling degradation beyond equilibrium occupancy.
- To evaluate the efficacy, tissue distribution, and protein knockdown capabilities of novel PROTAC compounds.
Main Methods:
- Development and application of novel heterobifunctional PROTAC molecules.
- Utilizing PROTACs to recruit target proteins to E3 ubiquitin ligases for ubiquitination and degradation.
- In vitro and in vivo (mouse studies) assessment of protein level reduction and tissue distribution.
Main Results:
- Two novel PROTACs achieved >90% specific protein level reduction at nanomolar concentrations.
- PROTACs demonstrated catalytic activity, degrading super-stoichiometric amounts of target proteins.
- Mouse studies confirmed broad tissue distribution and effective target protein knockdown in tumor xenografts.
Conclusions:
- Improved PROTACs represent a powerful chemical knockdown system with high efficacy and specificity.
- This technology combines the advantages of small-molecule drugs with the potency of RNAi and CRISPR.
- PROTACs offer a promising therapeutic strategy with potential to overcome limitations of traditional drug paradigms.
